Amendment: SEC Form SC 13D/A filed by Bioceres Crop Solutions Corp.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 10)*
Bioceres Crop Solutions Corp.
(Name of Issuer)
Ordinary Shares, $0.0001 par value
(Title of Class of Securities)
G1117K 114
(CUSIP Number)
Gloria Montaron Estrada
Bioceres Group PLC
Highdown House, Yeoman Way, Worthing,
West Sussex, United Kingdom
Telephone: +54 0341 4861100
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
Copy to:
Matthew S. Poulter
Linklaters LLP
1290 Avenue of the Americas
New York, NY 10104
September 18, 2024
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ¨
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See section 240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or other subject to the liabilities of that section of Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. G1117K 114
| 1 | Names of Reporting Person. Bioceres Group PLC | ||
| 2 | Check the Appropriate Box if a Member of a Group (a) x (b) ¨ | ||
| 3 | SEC Use Only | ||
| 4 | Source of Funds (See Instructions) N/A | ||
| 5 | Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ¨ | ||
| 6 | Citizenship or Place of Organization England and Wales | ||
| Number
of Shares Beneficially Owned by Each Reporting Person With |
7 | Sole Voting Power 6,924,868 | |
| 8 | Shared Voting Power (see Item 5 below) 22,664,919 (1) (2) | ||
| 9 | Sole Dispositive Power 6,924,868 | ||
| 10 | Shared Dispositive Power (see Item 5 below) 19,588,840 (1) | ||
| 11 | Aggregate Amount Beneficially Owned by Each Reporting Person 29,589,787 (1) | ||
| 12 | Check if the Aggregate Amount in Row (11) Excludes Certain Shares ¨ | ||
| 13 | Percent of Class Represented by Amount in Row (11) 47.1% | ||
| 14 | Type of Reporting Person HC | ||
(1) Bioceres Group PLC may be deemed to be the ultimate beneficial owner of Shares held by Bioceres LLC and THEO I SCSp as Bioceres LLC is an indirect wholly-owned subsidiary of Bioceres Group PLC, and Bioceres Group PLC owns 96.2% of the outstanding equity securities of THEO I SCSp.
(2) Includes 3,076,079 shares that Bioceres LLC has shareholder rights over pursuant to the Shareholders Agreement, dated as of March 5, 2019, by and between Bioceres LLC, Pedro Enrique Mac Mullen, María Marta Mac Mullen and International Property Services Corp. See Exhibit 10.1.
CUSIP No. G1117K 114
| 1 | Names of Reporting Person. Bioceres LLC | ||
| 2 | Check the Appropriate Box if a Member of a Group (a) x (b) ¨ | ||
| 3 | SEC Use Only | ||
| 4 | Source of Funds (See Instructions) N/A | ||
| 5 | Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ¨ | ||
| 6 | Citizenship or Place of Organization Delaware | ||
| Number
of Shares Beneficially Owned by Each Reporting Person With |
7 | Sole Voting Power — | |
| 8 | Shared Voting Power (see Item 5 below) 18,588,021 (1) (2) | ||
| 9 | Sole Dispositive Power — | ||
| 10 | Shared Dispositive Power (see Item 5 below) 15,511,942 (1) | ||
| 11 | Aggregate Amount Beneficially Owned by Each Reporting Person 18,588,021 (1) | ||
| 12 | Check if the Aggregate Amount in Row (11) Excludes Certain Shares ¨ | ||
| 13 | Percent of Class Represented by Amount in Row (11) 29.6% | ||
| 14 | Type of Reporting Person HC | ||
(1) Bioceres LLC is an indirect wholly-owned subsidiary of Bioceres Group PLC. As a result, Bioceres Group PLC may be deemed to be the ultimate beneficial owner of Shares held by Bioceres LLC.
(2) Includes 3,076,079 shares that Bioceres LLC has shareholder rights over pursuant to the Shareholders Agreement, dated as of March 5, 2019, by and between Bioceres LLC, Pedro Enrique Mac Mullen, María Marta Mac Mullen and International Property Services Corp. See Exhibit 10.1.
CUSIP No. G1117K 114
| 1 | Names of Reporting Person. THEO I SCSp | ||
| 2 | Check the Appropriate Box if a Member of a Group (a) x (b) ¨ | ||
| 3 | SEC Use Only | ||
| 4 | Source of Funds (See Instructions) N/A | ||
| 5 | Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ¨ | ||
| 6 | Citizenship or Place of Organization Grand Duchy of Luxembourg | ||
| Number
of Shares Beneficially Owned by Each Reporting Person With |
7 | Sole Voting Power — | |
| 8 | Shared Voting Power (see Item 5 below) 4,076,898 (1) | ||
| 9 | Sole Dispositive Power — | ||
| 10 | Shared Dispositive Power (see Item 5 below) 4,076,898 (1) | ||
| 11 | Aggregate Amount Beneficially Owned by Each Reporting Person 4,076,898 (1) | ||
| 12 | Check if the Aggregate Amount in Row (11) Excludes Certain Shares ¨ | ||
| 13 | Percent of Class Represented by Amount in Row (11) 6.5% | ||
| 14 | Type of Reporting Person HC | ||
(1) Bioceres Group PLC owns 96.2% of the outstanding equity securities of THEO I SCSp. As a result, Bioceres Group PLC may be deemed to be the ultimate beneficial owner of Shares held by THEO I SCSp.
CUSIP No. G1117K 114
EXPLANATORY NOTE
This Amendment No. 10 (the “Amendment”) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2019, (as amended by Amendment No. 1 filed with the SEC on July 2, 2020, Amendment No. 2 filed with the SEC on August 28, 2020, Amendment No. 3 filed with the SEC on November 25, 2020, Amendment No. 4 filed with the SEC on August 6, 2021, Amendment No. 5 filed with the SEC on October 15, 2021, Amendment No. 6 filed with the SEC on April 5, 2022, Amendment No. 7 filed with the SEC on July 25 2022, Amendment No. 8 filed with the SEC on November 15, 2022 and Amendment No. 9 filed with the SEC on March 25, 2024 (the “Schedule 13D”), by Bioceres Group PLC, Bioceres LLC and Theo I SCSp (each a “Reporting Person”, and herein collectively referred as the “Reporting Persons”).
This Amendment is being filed to report a change in the Shares beneficially owned by the Reporting Persons, as a result of a combination of open market sales made by the Reporting Persons, including certain open market sales entered by a party to the shareholders agreement described under Item 6 of the Schedule 13D (the “Transactions”). As a result of the foregoing, the Shares owned by the Reporting Persons changed from 27,663,487 to 26,513,708.
The Items below amend the information disclosed under the corresponding Items of the Schedule 13D as described below. Except as expressly amended and supplemented by this Amendment, the Schedule 13D is not amended or supplemented in any respect. Capitalized terms used but not otherwise defined in this Amendment have the meanings ascribed to such terms in the Schedule 13D.
The aggregate percentages of Shares beneficially owned by the Reporting Persons, and reported in this Amendment, is calculated based on 62,796,774 Shares outstanding, as reported by the Issuer in its annual report on Form 20-F filed with the SEC on November 14, 2023 (File No. 001-38405) (the “Issuer 20-F”).
| Item 2. | Identity and Background |
Item 2 of the Schedule 13D is hereby further amended and replaced as follows:
| (a) | This statement is filed by: |
| i) | Bioceres Group PLC, which is the holder of record of 6,924,868 Shares (corresponding to approximately 11.0% of the Issuer’s outstanding capital stock) and through its subsidiaries Bioceres LLC and Theo I SCSp, holds an additional 19,558,840 Shares (corresponding to approximately 31.2% of the Issuer’s outstanding capital stock); |
| ii) | Bioceres LLC, which is the holder of record of 15,511,942 Shares (corresponding to approximately 24.7% of the Issuer’s outstanding capital stock); and |
| iii) | THEO I SCSp, which is the holder of record of 4,076,898 Shares (corresponding to approximately 6.5% of the Issuer’s outstanding capital stock). |
All disclosures herein with respect to any Reporting Person are made only by such Reporting Person. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
| (b) | The address of the principal business and principal offices of: |
| i) | Bioceres Group PLC is Highdown House, Yeoman Way, Worthing, West Sussex, United Kingdom, BN99 3HH; |
| ii) | Bioceres LLC is 1209 Orange Street, Wilmington 19801-1120, County of New Castle; and |
| iii) | THEO I SCSp is 30 boulevard Royal, L-2449 Luxembourg. |
CUSIP No. G1117K 114
| (c) | Not applicable. |
(d) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanours).
(e) None of the Reporting Persons has, during the last five years, been a party to civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was, or is subject to, a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.
(f)
| i) | Bioceres Group PLC is a company organized under the laws of England and Wales; |
| ii) | Bioceres LLC is limited liability company formed under the laws of Delaware; and |
| iii) | THEO I SCSp is a special limited partnership (société en commandite spéciale) incorporated in the Grand Duchy of Luxembourg. |
| Item 3. | Source and Amount of Funds or Other Consideration. |
Please refer to the “Explanatory Note” of this Amendment.
| Item 4. | Purpose of the Transaction |
The purpose of the Transactions was to fund the payment of financial obligtions which were due.
As a result of the Transactions, the Shares owned by the Reporting Persons, which are not subject to the shareholders’ agreement described under Item 6 of the Schedule 13D, decreased from 27,663,487 Shares to 26,513,708 Shares. In addition, the number of Shares which the Reporting Persons have the shared power to vote or to direct the vote of, pursuant to the shareholders’ agreement described under Item 6 of the Schedule 13D, decreased from 3,167,145 Shares to 3,076,079 Shares due to the Transactions. As a result of the foregoing, in the aggregate, the Reporting Persons beneficially own 29,589,787 Shares (corresponding to approximately 47.1% of the Issuer’s outstanding capital stock).
Except for the foregoing, the Reporting Persons have no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D.
| Item 5. | Interest in Securities of the Issuer |
Item 5 of the Schedule 13D is hereby amended and replaced as follows:
(a)-(b) The aggregate percentages of Shares beneficially owned by the Reporting Persons, and reported in this Amendment, are calculated based on 62,796,774 Shares outstanding, as reported on the Issuer 20-F, as follows:
| Bioceres Group PLC | ||||
| a) | Amount beneficially owned: 29,589,787 | Percentage: 47.1% | ||
| b) | Number of shares to which the Reporting Person has: | |||
| i. | Sole power to vote or to direct the vote: | 6,924,868 | ||
| ii. | Shared power to vote or to direct the vote: | 22,664,919 | ||
| iii. | Sole power to dispose or to direct the disposition of: | 6,924,868 | ||
| iv. | Shared power to dispose or to direct the disposition of: | 19,588,840 | ||
CUSIP No. G1117K 114
| Bioceres LLC | ||||
| a) | Amount beneficially owned: 18,588,021 | Percentage: 29.6% | ||
| b) | Number of shares to which the Reporting Person has: | |||
| i. | Sole power to vote or to direct the vote: | — | ||
| ii. | Shared power to vote or to direct the vote: | 18,588,021 | ||
| iii. | Sole power to dispose or to direct the disposition of: | — | ||
| iv. | Shared power to dispose or to direct the disposition of: | 15,511,942 | ||
| THEO I SCSp | ||||
| a) | v. | Amount beneficially owned: 4,076,898 | Percentage: 6.5% | |
| b) | vi. | Number of shares to which the Reporting Person has: | ||
| vii. | Sole power to vote or to direct the vote: | — | ||
| viii. | Shared power to vote or to direct the vote: | 4,076,898 | ||
| ix. | Sole power to dispose or to direct the disposition of: | — | ||
| x. | Shared power to dispose or to direct the disposition of: | 4,076,898 | ||
(c) None of the Reporting Persons has effected any transactions of the Issuer’s Shares during the 60 days preceding the date of this report, except as described in Item 4 of this Schedule 13D/A which information is incorporated herein by reference.
(d) Not applicable.
(e) Not applicable.
| Item 7. | Material to be Filed as Exhibits |
| Exhibit 10.1* | Shareholders Agreement, dated as of March 5, 2019, by and between Bioceres LLC, Pedro Enrique Mac Mullen, María Marta Mac Mullen and International Property Services Corp. |
* Previously filed.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| BIOCERES GROUP PLC | ||
| By | /s/ Gloria Montaron Estrada | |
| Name: Gloria Montaron Estrada | ||
| Title: Attorney-in-Fact | ||
| Date: September 20, 2024 | ||
| BIOCERES LLC | ||
| By | /s/ Gloria Montaron Estrada | |
| Name: Gloria Montaron Estrada | ||
| Title: Manager | ||
| Date: September 20, 2024 | ||
| THEO I SCSp | ||
| By | /s/ Gloria Montaron Estrada | |
| Name: Gloria Montaron Estrada | ||
| Title: Attorney-in-Fact | ||
| Date: September 20, 2024 | ||